Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs.

The effects of modafinil and amphetamine on daytime sleep (polysomnographic recordings) and cataplexy (the food-elicited cataplexy test) were compared using the narcoleptic canine model. Results indicate that both modafinil (5 and 10 mg/kg body weight i.v.) and amphetamine (100 and 200 micrograms/kg i.v.) increase wakefulness and reduce slow-wave sleep in control and narcoleptic dogs. In contrast, the results of cataplexy testing demonstrate that amphetamine (2.5-160 micrograms/kg i.v.), but not modafinil (0.125-8.0 mg/kg i.v.) significantly suppresses canine cataplexy. These results suggest that the pharmacological property of modafinil is distinct from amphetamine. Results of polysomnographic recordings also demonstrate that narcoleptic dogs slept significantly more during the daytime than control dogs and required very high doses (10 mg/kg i.v. modafinil; 200 micrograms/kg i.v. amphetamine) of stimulants to reduce their level of sleepiness to that of control dogs. This finding is consistent with the data collected in human narcolepsy and validates the use of this canine model for the screening of stimulant compounds.

[1]  E. Mignot,et al.  Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[2]  E. Mignot,et al.  Neuropharmacology and neurochemistry of canine narcolepsy. , 1994, Sleep.

[3]  C. Guilleminault,et al.  Modafinil binds to the dopamine uptake carrier site with low affinity. , 1994, Sleep.

[4]  G. Koob,et al.  Narcolepsy and its treatment with stimulants. ASDA standards of practice. , 1994, Sleep.

[5]  F. Rambert,et al.  Lack of pre-synaptic dopaminergic involvement in modafinil activity in anaesthetized mice: In vivo voltammetry studies , 1994, Neuropharmacology.

[6]  M M Mitler,et al.  Treatment of narcolepsy with methamphetamine. , 1993, Sleep.

[7]  M. Mitler,et al.  The treatment of excessive somnolence with stimulant drugs. , 1993, Sleep.

[8]  C. Guilleminault,et al.  Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. , 1993, The Journal of pharmacology and experimental therapeutics.

[9]  J. Montplaisir,et al.  Effects of modafinil on symptomatology of human narcolepsy. , 1993, Clinical neuropharmacology.

[10]  M. Billiard,et al.  Effets du modafinil (300 mg) sur le sommeil, la somnolence et la vigilance du narcoleptique , 1993, Neurophysiologie Clinique/Clinical Neurophysiology.

[11]  C. Guilleminault,et al.  Genetically Determined Animal Models of Narcolepsy, A Disorder of REM Sleep , 1992 .

[12]  B. Saletu,et al.  On the treatment of the alcoholic organic brain syndrome with an alpha-adrenergic agonist modafinil: double-blind, placebo-controlled clinical, psychometric and neurophysiological studies , 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  C. Guilleminault,et al.  Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep. , 1990, The Journal of pharmacology and experimental therapeutics.

[14]  F. Rambert,et al.  Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. , 1990, European journal of pharmacology.

[15]  P. Anderer,et al.  Differential effects of the new central adrenergic agonist modafinil and d-amphetamine on sleep and early morning behaviour in elderlies. , 1989, Arzneimittel-Forschung.

[16]  D. L. Reeves,et al.  Sustained/Continuous Operations Subgroup of the Department of Defense Human Factors Engineering Technical Group. Program Summary and Abstracts from the Semiannual Meeting (8th). , 1989 .

[17]  M. Jouvet,et al.  Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil , 1988, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[18]  C. Guilleminault,et al.  Role of central alpha-1 adrenoceptors in canine narcolepsy. , 1988, The Journal of clinical investigation.

[19]  E. Sundström,et al.  Differential time course of protection by monoamine oxidase inhibition and uptake inhibition against MPTP neurotoxicity on central catecholamine neurons in mice. , 1986, European journal of pharmacology.

[20]  E. Sundström,et al.  Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. , 1985, European journal of pharmacology.

[21]  J. Poignant [Amineptine, a new antidepressant: pharmacological review (author's transl)]. , 1979, L'Encephale.

[22]  L. Simpson The effect of behavioral stimulant doses of amphetamine on blood pressure. , 1976, Archives of general psychiatry.

[23]  C. Marsden,et al.  NATURAL HISTORY, SYMPTOMS AND TREATMENT OF THE NARCOLEPTIC SYNDROME , 1975, Acta neurologica Scandinavica.

[24]  J. Scheel-Krüger,et al.  Some aspects of the mechanism of action of various stimulant amphetamine analogues. , 1972, Psychiatria, neurologia, neurochirurgia.

[25]  Y. Honda [Treatment of narcolepsy]. , 1965, Saishin igaku. Modern medicine.

[26]  W. Ganado The narcolepsy syndrome. , 1958, Neurology.